-
Correvio Pharma In The Spotlight Amid Brinavess Adcom Verdict
Tuesday, December 10, 2019 - 11:49am | 477Correvio Pharma Corp (NASDAQ: CORV) shares came under selling pressure Friday after a briefing document released ahead of the company's planned Adcom meeting showed that FDA staffers were not convinced that the benefits of its atrial fibrillation medication Brinavess outweigh the risks. ...
-
Canaccord: Cardiome Pharma's Sale Of Canadian Business 'A Highly Positive Catalyst' For Shares
Wednesday, March 21, 2018 - 4:36pm | 369CARDIOME PHARMA CORP (NASDAQ: CRME) announced Tuesday it has agreed to divest its Canadian business to Cipher Pharmaceuticals for the U.S. dollar equivalent of $19.7 million. The Analyst Canaccord Genuity's Dewey Steadman maintains a Buy rating on Cardiome's stock with an unchanged...